Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future
Open accessAbstract
Coronavirus disease 2019 (COVID-19) has posed unprecedented challenges for nations worldwide, among which medication shortages can cause a devastatingly negative impact on global health. Using Taiwan as an example, this report describes the sources of potential medication shortages, discusses the preparedness and contingency strategies to address medication shortages, and outlines the evidence-based recommendations on ensuring a stable medication supply and improving the quality and security of medicines. Many drug shortages have focused on shortfalls of overseas manufacturing, but the effect of the COVID-19 crisis on misallocation of medications within the nation's internal supply chains is also a great concern. A wide range of stakeholders are involved in pharmaceutical supply chains, including government regulators, health care insurers, pharmaceutical companies, frontline physicians and pharmacists, patients and families, professional and patient associations or unions, and even individuals who acquire medications from abroad. Collaborative inputs and efforts from all these interdependent stakeholders are critical for establishing transparent preparedness and contingency plans to address drug shortages affected by disruptions of overseas manufacturing or stockouts in pharmacies owing to medication misallocation. Strategies have been documented and recommended in Taiwan and the United States to mitigate drug shortages and ensure the long-term quality and security of medicines. Barriers to accessing medicines are nothing new, but the COVID-19 pandemic poses urgent and even novel challenges to the stability and integrity of medication supply, which urges for a need to reconsider and reinforce effective management strategies for pharmaceuticals. Active management, transparent information, and timely communications are essential to ensure a stable supply of key therapeutic medications, especially during a pandemic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The challenges in Nigeria and other countries like Taiwan have been further complicated by the COVID-19 pandemic.
“It is important to note that the challenges in Nigeria and other countries like Taiwan have been further complicated by the COVID-19 pandemic [46, 47].”
From Medicines and vaccines supply chains challenges in Nigeria: a scoping review (2022) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing
Wang, C. J., Ng, C. Y., & Brook, R. H. (2020) · JAMA · doi:10.1001/jama.2020.3151 · Cited by 1,391 · see citing works
Self-citationPolicy Decisions and Use of Information Technology to Fight Coronavirus Disease, Taiwan
Lin, C., Braund, W. E., Auerbach, J., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2607.200574 · Cited by 141 · see citing works
Ensuring Access to Medications in the US During the COVID-19 Pandemic
Alexander, G. C., & Qato, D. M. (2020) · JAMA · doi:10.1001/jama.2020.6016 · Cited by 94 · see citing works
Ou, H., & Yang, Y. K. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1404 · Cited by 26 · see citing works
Self-citationShortcomings in the US Pharmaceutical Supply Chain
Oehler, R. L., & Gompf, S. (2020) · JAMA · doi:10.1001/jama.2020.1634 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Medicines and vaccines supply chains challenges in Nigeria: a scoping review
Olutuase, V. O., Iwu-Jaja, C. J., Akuoko, C. P., Adewuyi, E. O., & Khanal, V. (2022) · BMC Public Health · doi:10.1186/s12889-021-12361-9 · Cited by 99 · see citing works
- Authors
- Kuo, S., Ou, H.-T., & Wang, C. J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Kuo, Shihchen
- Venue
- Journal of the American Pharmacists Association
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 61
- Issue
- 1
- Pages
- e12-e15
- ISSN
- 1544-3191 (ISSN-L)
- PMC
- PMC7439991
- OpenAlex
- W3072351405
- Cited by
- 47
- References
- 5
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 2
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the American Pharmacists Association (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Business, Management and Accounting › Strategy and Management › Supply Chain Resilience and Risk Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- drug shortages, pharmaceutical supply chain, COVID-19 pandemic, contingency planning, stakeholder collaboration, Taiwan, United States
- MeSH terms
- COVID-19, Disaster Planning, Drug Industry, Pharmaceutical Preparations, Humans, Taiwan, United States, Global Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review